All patients, n = 92 | Patients without thrombotic events, n = 55 (60%) | Patients with thrombotic events, n = 37 (40%) | p | |
---|---|---|---|---|
Age (years) | 61 [55–70] | 61 [55–69] | 62 [54–71] | 0.89 |
Male, n (%) | 73 (79) | 44 (80) | 29 (78) | 0.55 |
Body mass index (kg/m2) | 30 [26–35] | 32 [25–36] | 29 [27–34] | 0.34 |
Baseline SOFA | 4 [3–7] | 4 [2–7] | 4 [3–8] | 0.6 |
Baseline SAPS II | 31 [21–40] | 31 [20–39] | 31 [22–44] | 0.8 |
Main comorbidities,n(%) | ||||
Hypertension | 59 (64) | 36 (65) | 23 (62) | 0.75 |
Diabetes mellitus | 35 (38) | 22 (40) | 13 (35) | 0.75 |
Cardio-vascular diseases | 9 (10) | 8 (14) | 1 (3) | 0.48 |
Atrial fibrillation | 3 (3) | 1 (2) | 2 (5) | 0.06 |
Cerebro-vascular diseases | 8 (9) | 5 (9) | 3 (8) | 0.34 |
Venous thrombo-embolism | 5 (5) | 3 (5) | 2 (5) | 0.89 |
Chronic respiratory diseases | 18 (20) | 11 (20) | 7 (19) | 0.99 |
Chronic renal failure | 7 (8) | 7 (13) | 0 | 0.03 |
Laboratory measurements at ICU admission | ||||
Fibrinogen (g/L) | 7.8 [6.1–8.8] | 7.5 [6.0–8.6] | 7.9 [6.3–9] | 0.45 |
D-dimers (μg/mL) | 2.4 [1.7–7.9] | 2.2 [1.2–5.9] | 4.4 [1.8–2] | 0.03 |
Prothrombin time (%) | 86 [76–96] | 92 [80–100] | 79 [68–90] | < 0.001 |
Platelets (G/L) | 227 [182–307] | 213 [170–302] | 235 [198–340] | 0.17 |
Thromboprophylaxis strategy | ||||
Usual (prophylactic) anticoagulation | 43 (47) | 26 (47) | 17 (46) | 0.90 |
Full-dose (therapeutic) anticoagulation | 49 (53) | 29 (53) | 20 (54) | 0.90 |
Outcome in ICU,n(%) | ||||
Invasive mechanical ventilation | 82 (89) | 46 (84) | 36 (97) | 0.04 |
Prone positioning | 55 (60) | 32 (58) | 23 (62) | 0.70 |
Vasopressor support | 57 (62) | 31 (56) | 26 (70) | 0.18 |
Renal replacement therapy | 22 (24) | 11 (20) | 11 (30) | 0.28 |
ICU mortality* | 38 (41) | 20 (36) | 18 (49) | 0.24 |
Still hospitalized in ICU* | 25 (27) | 13 (24) | 12 (32) | 0.35 |
Discharged to the wards* | 28 (30) | 21 (38) | 7 (19) | 0.05 |